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Each year, urinary catheters are inserted in more than 5
million patients in acute-care hospitals and extended-care
facilities. Catheter-associated urinary tract infection (CAUTI)
is the most common nosocomial infection in hospitals and
nursing homes, comprising >40% of all institutionally
acquired infections (1-4). Nosocomial bacteriuria or candiduria
develops in up to 25% of patients requiring a urinary catheter
for > 7 days, with a daily risk of 5% (5-7). CAUTI is the second
most common cause of nosocomial bloodstream infection
(8-10), and studies by Platt et al. (11) and Kunin et al. (12)
suggest that nosocomial CAUTIs are associated with
substantially increased institutional death rates, unrelated
to the occurrence of urosepsis. Although most CAUTIs are
asymptomatic (13), rarely extend hospitalization, and add
only $500 to $1,000 to the direct costs of acute-care
hospitalization (14), asymptomatic infections commonly
precipitate unnecessary antimicrobial-drug therapy. CAUTIs
comprise perhaps the largest institutional reservoir of
nosocomial antibiotic-resistant pathogens (5-10,15), the most
important of which are multidrug-resistant Enterobacteriacae
other than Escherichia coli, such as Klebsiella, Enterobacter,
Proteus, and Citrobacter; Pseudomonas aeruginosa; enterococci
and staphylococci; and Candida spp. (Table 1).
Pathogenesis
Excluding rare hematogenously derived pyelonephritis,
caused almost exclusively by Staphylococcus aureus, most
microorganisms causing endemic CAUTI derive from the
patient’s own colonic and perineal flora or from the hands of
health-care personnel during catheter insertion or manipula-
tion of the collection system. Organisms gain access in one of
two ways (Figure 1). Extraluminal contamination may occur
early, by direct inoculation when the catheter is inserted, or
later, by organisms ascending from the perineum by capillary
action in the thin mucous film contiguous to the external
catheter surface. Intraluminal contamination occurs by
reflux of microorganisms gaining access to the catheter lumen
from failure of closed drainage or contamination of urine in
the collection bag.
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Table 1. Microbial pathogens causing nosocomial catheter-associated
urinary tract infections in U.S. acute-care hospitals, 1990-92 (15)
Intensive
Hospitalwide care units
Pathogens  (% of total) (% of total)
Escherichia coli 26 18
Enterococci 16 13
Pseudomonas aeruginosa 12 11
Klebsiella and Enterobacter spp. 12 13
Candida spp.   9 25
Figure l. Routes of entry of uropathogens to catheterized urinary
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Recent studies suggest that CAUTIs most frequently
stem from microorganisms gaining access to the bladder
extraluminally, but both routes are important (Table 2) (16).
Some studies suggest that the extraluminal route may be of
greater relative importance in women because of the short
urethra and its close proximity to the anus (17). Investigators
have found that antecedent heavy periurethral cutaneous
colonization is an important risk factor for CAUTI in both
men and women (17,18).
Most infected urinary catheters are covered by a thick
biofilm containing the infecting microorganisms embedded in
a matrix of host proteins and microbial exoglycocalyx (Figure
2). A biofilm forms intraluminally, extraluminally, or both
ways, usually advancing in a retrograde fashion (19). The role
of the biofilm in the pathogenesis of CAUTI has not been
established. However, antiinfective-impregnated and silver-
hydrogel catheters (20-26), which inhibit adherence of
microorganisms to the catheter surface, significantly reduce
the risk of CAUTI, particularly infections caused by gram-
positive organisms or yeasts, which are most likely to be
acquired extraluminally from the periurethral flora (16).
These data suggest that microbial adherence to the catheter
surface is important in the pathogenesis of many, but not all,
CAUTIs. Infections in which the biofilm does not play a
pathogenetic role are probably caused by mass transport of
intraluminal contaminants into the bladder by retrograde
reflux of microbe-laden urine when a catheter or collection
system is moved or manipulated (Figure 1, Table 2).
A prospective study in which catheterized patients were
cultured daily by a technique capable of detecting very low-
level bacteriuria, as low as 1 CFU/mL (7), showed that
isolation of any microorganisms from an intraluminal
specimen, even 3-4 CFU/mL, is highly predictive of CAUTI. If
intercurrent antimicrobial therapy is not given, the level of
bacteriuria or candiduria almost uniformly increases to >105
within 24-48 hours (Figure 3), demonstrating the vulnerabil-
ity of the catheterized urinary tract to infection once any
Table 2. Mechanisms of catheter-associated urinary tract infection,
based on a prospective study of 1,497 newly catheterized patients who
had 235 new-onset infections (16)
               Organisms causing CAUTIa
Gram- Gram-
positive negative
Mechanism  cocci Yeasts bacilli Overall
of CAUTI (n=44) (n=34) (n=37) (n=115)
Extraluminal 79% 69% 54% 66%
Intraluminal 21% 31% 46% 34%
aPercentages refer to organisms in which the mechanism of infection
could be determined. For comparison of gram-positive cocci and
yeasts vs. gram-negative bacilli, p = 0.007.
CAUTI = catheter-associated urinary tract infection.
Figure 2. Scanning electron micrograph of an infected catheter
showing dense and complex biofilm on the extraluminal surface.
Urine culture at catheter removal yielded Candida albicans 104 CFU/
mL and C. glabrata 104 CFU/mL (X 5000).
Figure 3. Rate of progression of bacteriuria and candiduria in 25
catheterized patients once any microorganisms were detectable in
urine culture. Once organisms appeared in urine, low-level
bacteriuria progressed very rapidly to levels >105 organisms per
milliliter in 12 of the 14 cases within 2 days. Candiduria progressed
less rapidly: in 9 of 11 cases, a concentration of >105 organisms per
milliter was reached within 3 days (7).344 Emerging Infectious Diseases Vol. 7, No. 2, March–April 2001
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microorganisms gain access to the lumen of the catheter and
the bladder. The very heavy use of systemic antimicrobial
drugs in catheterized patients, which has been found in most
studies (5-13), probably keeps the rate of CAUTI considerably
lower than it would be otherwise, but unfortunately selects for
the resistant organisms that produce most nosocomial
CAUTIs (Table 1).
Definition of CAUTI
Most clinicians use a clean-voided specimen showing
>105 CFU/mL as the criterion for “significant” bacteriuria
(i.e., true infection) for noncatheterized patients (4). However,
once any microorganisms are identified in urine from a
patient’s indwelling catheter, unless suppressive antimicro-
bial-drug therapy is being given or started, progression to
concentrations >105 CFU/mL occurs predictably and rapidly,
usually within 72 hours (Figure 3) (7). Thus, most authorities
consider concentrations >102 or 103  CFU/mL, in urine
collected with a needle from the sampling port of the catheter,
to be indicative of true CAUTI. This concentration can be
reproducibly detected in the laboratory, and this definition is
useful for therapeutic decisions and epidemiologic research
(1-7).
Risk Factors for CAUTI
Large, prospective studies in which catheterized patients
were cultured daily and which used multivariable techniques
of statistical analysis identified risk factors independently
predictive of increased risk for CAUTI (27-30; Table 3).
Females have a substantially higher risk than males (relative
risk [RR] 2.5-3.7), and patients with other active sites of
infection (RR 2.3-2.4) or a major preexisting chronic condition
(such as diabetes [RR 2.2-2.3], malnutrition [RR 2.4], or renal
insufficiency [RR 2.1-2.6]) also are at higher risk. Inserting
the catheter outside the operating room (RR 2.0-5.3) or late in
hospitalization (RR 2.6-8.6), presence of a ureteral stent
(RR 2.5), or using the catheter to measure urine output (RR
2.0) further increase the risk.
The most important, potentially modifiable risk factor,
identified in every study, is prolonged catheterization, beyond
6 days (RR 5.1-6.8); by the 30th day of catheterization,
infection is near-universal. A large, prospective study
monitored compliance on a daily basis with seven
recommended precepts for catheter care, including closed
drainage, dependent drainage including proper position of the
drainage tubing and collection bag, and protection of the
drainage port; the only violation predictive of an increased
risk of CAUTI was improper position of the drainage tube,
above the level of the bladder or sagging below the level of the
collection bag (RR 1.9) (27).
Antimicrobial-drug therapy has been shown to be
protective against CAUTI for short-term catheterizations
(RR 0.001-0.4) but clearly selects for infection caused by
multidrug-resistant microorganisms, such as P. aeruginosa,
and other resistant gram-negative bacilli, enterococci, and
yeasts (Table 1) (1-10,15).
Guidelines for Preventing CAUTI
Several catheter-care practices are universally recom-
mended to prevent or at least delay the onset of CAUTI: avoid
unnecessary catheterizations; consider a condom or suprapu-
bic catheter; have a trained professional insert the catheter
aseptically; remove the catheter as soon as no longer needed;
maintain uncompromising closed drainage; ensure depen-
dent drainage; minimize manipulations of the system; and
separate catherized patients (1-4). However, few of these
practices have been proven to be effective by randomized
controlled trials.
Avoid Unnecessary Catheterizations
Use of indwelling urethral catheters should be limited to
patients requiring relief of anatomic or physiologic outlet
obstruction; patients undergoing surgical repair of the
genitourinary tract (to facilitate healing); critically ill or
postoperative patients who need their urinary output
accurately measured; and debilitated, paralyzed, or comatose
patients (to prevent skin breakdown and infected pressure
ulcers). When no longer needed, the catheter should be
promptly removed (31).
Consider Alternatives to Urethral Catheterization
Suprapubic catheterization is more comfortable and
acceptable to the patient and may be associated with a lower
incidence of CAUTI (32). For incontinent males who do not
have bladder outlet obstruction, condom drainage, while not
free from nosocomial urinary tract infections, appears to be
associated with a lower risk than indwelling urethral
catheters (33).
Insertion Using Aseptic Technique
Catheters should be inserted by trained health-care
professionals using aseptic technique, including sterile
gloves, a fenestrated sterile drape, and an effective cutaneous
antiseptic, such as 10% povidone-iodine or 1% to 2% aqueous
chlorhexidine.
Closed Drainage
After a catheter is inserted, uncompromising mainte-
nance of closed drainage is of the highest priority and can keep
the overall risk of CAUTI <25% for up to 2 weeks of
catheterization (5,6).
Ensure Dependent Drainage
The collection tubing and bag should always remain
below the level of the patient’s bladder, but the drainage
tubing should always be above the level of the collection bag.
Table 3. Risk factors for catheter-associated urinary tract infection,
based on prospective studies and use of multivariable statistical
modeling (27-30)
Factor Relative risk
Prolonged catheterization >6 days 5.1-6.8
Female gender 2.5-3.7
Catheter insertion outside operating room 2.0-5.3
Urology service 2.0-4.0
Other active sites of infection 2.3-2.4
Diabetes 2.2-2.3
Malnutrition 2.4
Azotemia (creatinine >2.0 mg/dL 2.1-2.6
Ureteral stent 2.5
Monitoring of urine output 2.0
Drainage tube below level of bladder 1.9
   and above collection bag
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In one large prospective study, this was the only catheter-care
violation associated with a significantly increased risk of
CAUTI (RR 1.9) (27).
Urine Collection
The catheter and the drainage system should be
manipulated as little as possible, and urine output should be
monitored hourly only when clearly indicated by the patient’s
condition.
Other Practices
If feasible, separating catheterized patients geographi-
cally on a patient-care unit may reduce the risk of cross-
infection with multidrug-resistant nosocomial organisms
such as Serratia, Klebsiella, Pseudomonas, and Enterobacter
(34).
Systemic antimicrobial prophylaxis with trimethoprim-
sulfamethoxazole, methenamine mandelate or, especially, a
fluoroquinolone, can reduce the risk of CAUTI for short-term
catheterizations (35). Although use of antimicrobials in this
way may reduce the rate of CAUTI, infections that do occur
are far more likely to be caused by antibiotic-resistant
bacteria and yeasts (1-10). Since most CAUTIs are
asymptomatic and do not result in urosepsis (13), it is difficult
to justify antimicrobial therapy of asymptomatic bacteriuria
other than for granulocytopenic or other severely
immunocompromised patients, patients scheduled for
urologic surgery, pregnant women, patients with Serratia
CAUTI, or patients about to have their catheter removed. The
societal benefits of antibiotic prophylaxis in immunocompe-
tent catheterized patients to prevent largely asymptomatic
CAUTIs are dubious.
Novel Technology
Technologic innovations to prevent nosocomial infection
are most likely to be most effective if they are based on a clear
understanding of the pathogenesis and epidemiology of the
infection (36). Novel technologies must be designed to block
CAUTI by either the extraluminal or intraluminal routes or
both (Figure 1). Technologic innovations have been proposed
and evaluated during the past 25 years but have not proven
conclusively beneficial (1-5). Among these innovations are
using antiinfective lubricants when inserting the catheter;
soaking the catheter in an antiinfective antimicrobial-drug
solution before insertion; regular metal cleansing or
periodically applying antiinfective creams or ointments to
metals; continuously irrigating the catheterized bladder with
an antiinfective solution through a triple-lumen catheter; or
periodically instilling an antiinfective solution into the
collection bag (Table 4). Bladder irrigation with antimicro-
bial-drug solutions has not only shown no benefit for
prevention but has been associated with a strikingly
increased proportion of CAUTIs caused by microorganisms
resistant to the drugs in the irrigating solution (37).
Given the widely accepted importance of closed catheter
drainage, efforts have been made to seal the connection
between the catheter and collection tubing. An initial trial
with a novel catheter showed a modest benefit and suggested
a reduction in hospital deaths (38); however, follow-up studies
have not demonstrated a reduction in CAUTI with a sealed
catheter-collecting tube junction (39,40).
Medicated catheters, which reduce adherence of
microorganisms to the catheter surface, may confer the
greatest benefit for preventing CAUTI. Two catheters
impregnated with antiinfective solutions have been studied
in randomized trials, one impregnated with the urinary
antiseptic nitrofurazone (20) and the other with a new broad-
spectrum antimicrobial-drug combination, minocycline and
rifampin (21). Both catheters showed a significant reduction
in bacterial CAUTIs; however, the studies were small, and
selection of antimicrobial-drug resistant uropathogens was
not satisfactorily resolved.
The universal presence of a biofilm on the surface of an
infected catheter (19) (Figure 2) has prompted hope that
coating the catheter surface with an antiseptic, such as a
silver compound, might reduce the risk for CAUTI. However,
silver oxide-coated catheters, which had been initially
reported to show promise, did not show efficacy when studied
in large, well-controlled trials (29,30). In one of the trials,
male patients with the coated catheter who did not receive
systemic antibiotics had a paradoxical and inexplicably
increased risk for CAUTI (30).
A silver-hydrogel catheter has been developed that
inhibits adherence of microorganisms to the catheter surface
in vitro; tested microorganisms include resistant enterococci,
staphylococci, Enterobacteriaceae, P. aeruginosa, and yeasts
(41). Small comparative but nonblinded trials have shown
this product prevents CAUTI (22-25,42) (Figure 4). In a
recent, large, double-blinded trial in 850 patients (26), the
silver-hydrogel catheter reduced the incidence of CAUTI 26%
(25.7 vs. 15.4 per 100 catheters, RR 0.74, p =0.04) (27). The
greatest benefit was preventing infections caused by gram-
positive organisms, enterococci and staphylococci (RR 0.45, p
<0.001), and Candida (RR 0.80), microorganisms that usually
gain access to the bladder extraluminally (16). The catheter
conferred no protection against CAUTIs with gram-negative
bacilli, which most often gain access intraluminally (16). Use
of the silver-hydrogel catheter was not associated with an
increased incidence of infections caused by antibiotic-
resistant bacteria or Candida, and in vitro susceptibility
testing of isolates from both treatment groups showed no
infections caused by silver-resistant microorganisms. Cost-
utility analysis indicates that use of this catheter could bring
substantial cost savings to health-care institutions (Table 5).
Table 4. Studies of novel technologies for preventing catheter-
associated urinary tract infection
Risk reduction in
Technologic innovation (ref) randomized trials
Antiinfective lubricant (2) Unproven
Sealed catheter-collection tubing Unproven
  junctions (38-40)
Antireflux valves (2) Unproven
Continuous irrigation of bladder Unproven
  with antiinfective solution (2,37)
Instillation of antiinfective into Unproven
  collection bag (2)
Antiinfective catheter material
  Antimicrobial drug-impregnated
    Nitrofurazone (20)   0.7 (0.3a)
    Minocycline-rifampin (21)   0.4
  Silver oxide (29,30,42) Unproven
  Silver-hydrogel (22-25,26,42)   0.2-0.7
CAUTI = catheter-associated urinary tract infection.
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The Future
The first major advance for preventing CAUTI since the
wide-scale adoption of closed drainage 35 years ago is the
development of catheters with antiinfective surfaces. These
advances should not be considered the final answer, however.
Other technologies that should be pursued include new, more
potent antiinfective materials; microbe-impervious antire-
flux valves; urethral stents; conformable (collapsible)
urethral catheters; and vaccines for enteric gram-negative
bacilli and staphylococci. Antiseptics are far more likely than
antibacterials to confer greater resistance to surface
colonization and not to select for infection with antimicrobial-
drug resistant bacteria or yeasts (43). New surface
technologies that release far greater quantities of ionic silver
or other antiinfective agents into the aqueous environment
Figure 4. Meta-analysis of published prospective randomized trials of
silver oxide and silver alloy-hydrogel catheters. Data suggest that
silver-hydrogel catheters can substantially reduce the risk for
CAUTI (42).
Table 5. Cost-benefit evaluation (restricted to direct hospital costs) of
the silver-hydrogel catheter
Assumptions of analysis
Proportion of CAUTIs diagnosed  clinically      65%
Cost of each diagnosed CAUTI  ~$1000a
Added acquisition cost of a silver-hydrogel catheter        ~$5
Incremental hospital costs, per 100 catheters:
  Using standard urinary catheters $17,000
    (26 CAUTIs, 17 diagnosed)
  Using silver-hydrogel catheters $10,000
    (15 CAUTIs, 10 diagnosed)
    Added cost of catheters      $500b
    Total costs $10,500
Potential savings per 100 catheters   $6,500
aBased on studies showing that a diagnosed nosocomial CAUTI adds
approximately $1,000 to direct costs of hospitalization (14);
CAUTI = catheter-associated urinary tract infection.
bCost of preventing a CAUTI: approximately $71.
contiguous to the catheter surface might even prevent
CAUTIs caused by intraluminal contaminants.
In uncontrolled trials, urethral stents have provided a
less-invasive alternative to catheter drainage for men with
outlet obstruction caused by prostatic hypertrophy or cancer
(44). A conformable catheter, with a collapsible intraurethral
segment that may cause less trauma to the urethra, has been
developed but has not been tested clinically and is not
commercially available. These and other alternatives to the
rigid urethral catheter, such as a condom catheter for female
patients (45), need to be evaluated in controlled, randomized
trials.
The greatest hope for a major reduction in CAUTI and
indeed all nosocomial infections is likely to be vaccines
against important nosocomial multidrug-resistant patho-
gens, such as the enteric gram-negative bacilli and
staphylococci.
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